I don’t agree with Aubrey de Grey in the round about ageing, but I think his approach to the science is good. However, I note that I am putting up quite a few vidoes in which he appears and I may stop doing this because they are likely to be quite similar. Still:
chatGPT:
Tidy transcript
Longevity Technology Unlocked — Interview with Aubrey de Grey
Topic: Longevity escape velocity (LEV), repair-based rejuvenation, mouse studies, AI, regulation, access, and the future of aging medicine.
Chapter 1: Repairing damage vs slowing aging
Phil Newman: Welcome to Longevity Technology Unlocked. I’m Phil Newman.
Dr. Nina Patrick: And I’m Dr. Nina Patrick. Today we’re exploring one of the boldest ideas in longevity science: longevity escape velocity, or LEV.
Phil Newman: The basic idea is that medical advances could eventually extend life faster than aging processes shorten it. To help explain this, we’re joined by Aubrey de Grey, founder, president, and chief science officer of the LEV Foundation, a biomedical research and advocacy charity focused on repairing the molecular and cellular damage of aging.
Before we get into the science, let’s start with something more personal. Aubrey, you work hard on this mission every day. Do you apply any of this to your own personal longevity, or are you mainly focused on the broader mission?
Aubrey de Grey: Those are not mutually exclusive. Having a purpose in life, a reason to get out of bed, is one of the best things one can do for longevity. I feel privileged to be able to contribute to what I regard as humanity’s biggest problem. It’s a great privilege, and I think it keeps me young.
Phil Newman: LEV is one of the most discussed ideas in longevity science. For someone hearing it for the first time, how would you explain what it means?
Aubrey de Grey: I coined the term more than 20 years ago. For a long time, the expert community avoided it because of what it implied about how long people alive today might live.
The concept came from the idea that repairing the damage of aging—that is, genuinely rejuvenating people by reducing their biological age—will be medically easier than significantly slowing aging down.
That was counterintuitive at first, but the consequence is this: once we can rejuvenate people to a meaningful degree, we may be able to buy them perhaps 20 extra years of healthy life. Not for children born today, but for people already in middle or later life—say in their 60s or 70s—who are not yet seriously ill but are approaching the age when chronic diseases typically appear.
If we can restore such a person to the biological state of, say, a 40-year-old, then we buy time. Twenty years is a long time in biomedical research. During that time, the rejuvenation technologies themselves can improve enough that when the same person is biologically old again, we can re-rejuvenate them. Then the process could repeat.
Chapter 2: Rejuvenation cycles and buying 20 years of time
Phil Newman: I’m 58, so this is getting personally interesting. Are there assumptions built into this narrative about the pace of medical progress? Are there milestones you look for?
Chapter 3: Timeframes, probabilities, and “make aging the new Covid”
Aubrey de Grey: Yes, but because this is pioneering technology, everything has to be framed probabilistically. I think there is a 50% chance of reaching LEV—meaning enough progress to stay one step ahead of aging—within the next 12 to 15 years.
What leads me to that estimate is the rate of progress, and also the broader societal context. My current slogan is that we must make aging the new Covid. Humanity’s response to Covid showed that when society decides something matters, we can abolish regulatory inertia and bureaucratic delay. Vaccines were developed and distributed globally at unprecedented speed.
Dr. Nina Patrick: If we imagine approaching LEV in 12 to 15 years, what would be one specific breakthrough you would expect to see along that path?
Aubrey de Grey: Not one technological breakthrough, but one outcome from combining multiple breakthroughs. And somewhat counterintuitively, the key thing will be progress in mice.
People may say, “Why mice?” Because the public doesn’t care about mice—but the people the public listens to do care what experts say, and experts care about mice.
Over the past 50 years, there has effectively been no major progress in late-life lifespan extension in mice beyond what was already possible decades ago. In the 1970s, calorie restriction could extend the life of middle-aged mice by a few months. Later, rapamycin could do roughly the same.
If we could extend lifespan in middle-aged mice by 8 to 12 months instead of 4 months, experts would immediately know we had entered a new era. Then they would say so publicly, influencers would amplify it, governments would respond, and the field would change overnight.
Chapter 4: Mouse lifespan extension as the field’s proof point
Phil Newman: That’s the plan, then.
[Sponsor segment omitted from analysis; it promoted “Fatty15” and C15:0 supplements.]
Chapter 5: Why repair is the most practical framework
Phil Newman: Your approach focuses on repairing the damage that accumulates with age rather than slowing aging itself. Why do you think repair is the most practical framework?
Aubrey de Grey: Because it works. I often show a slide of a 100-year-old vintage car that still works well. It’s not because it was built to last 100 years; it’s because people who loved it gave it unusually comprehensive maintenance.
Preventive maintenance works. The question is: what is different about the human body?
One big difference is that the body is vastly more complex than anything we have built, and we did not design it, so we understand it poorly. But the other difference works in our favor: the body is full of sophisticated self-maintenance machinery. It is very good at preventing disease for a long time.
So our job is not to fix every detail. It is to augment the body’s own maintenance systems—to fill in the gaps.
Dr. Nina Patrick: But with many rejuvenation therapies being developed, combining them could lead to unexpected interactions or risks, including cancer. How do you think about that?
Aubrey de Grey: You’re absolutely right. Medicine differs from most other kinds of engineering because when you combine components in a system you don’t fully understand, surprises can happen.
My approach has long been “divide and conquer”: identify different classes of damage and repair each with a different intervention. That means doing several things at once in the same individual. But yes, phase two—combining them—can produce surprises.
A current example is partial epigenetic reprogramming. I think there is still a substantial risk that the current ways of doing it could increase cancer risk. That is not necessarily a showstopper, but it must be taken very seriously.
Dr. Nina Patrick: How should we test those therapies safely?
Aubrey de Grey: The cancer field has developed increasingly powerful ways to detect cancer early—mutant cells, neoantigen expression, and so on. Those tools will be very important.
One challenge is that reprogramming work has mostly been developed in short-lived organisms such as mice. But if the real risk is in promoting early stages of carcinogenesis, that may be difficult to see in short-lived animals. So we need to use every advanced early-detection method we have.
Chapter 6: What result would convince the scientific community
Phil Newman: Let’s talk about the LEV Foundation’s Robust Mouse Rejuvenation program. How is it designed, and what are you trying to achieve?
Aubrey de Grey: The main goal is to change the zeitgeist—society’s attitude toward whether aging is malleable. We do not mainly care whether the exact same interventions will work in humans. If something robustly works in mice, it breaks the sense that aging is inherently untouchable.
We structure the program by combining interventions that have already shown meaningful effects in middle-aged mice—ideally lifespan effects when started around 18 months of age.
When we designed the first study, there were not many such interventions, so we combined four, including rapamycin as a positive control. That first study went reasonably well, but we did not break through the four-month “glass ceiling.”
Since then, many more papers have appeared showing late-life lifespan extension from additional interventions. So now we want to test a much broader portfolio.
Phil Newman: What were the interventions in the first study?
Aubrey de Grey: Rapamycin was included mainly as a positive control. The other three were more directly “damage repair” oriented:
- Telomerase gene therapy
- Heterochronic bone marrow transplantation
- A senolytic
Telomerase gene therapy had already shown benefits in late-life mice. Heterochronic bone marrow transplant involves transplanting stem cells from young mice into old mice. And senolytics remove senescent “zombie” cells that secrete harmful factors.
Phil Newman: And now you’ve added more?
Aubrey de Grey: We would love to run many more studies in parallel if we had vastly more money, because there are lots of interventions and dosage questions.
In the current study, we are not simply reusing the original set. We have a newer, more promising senolytic, and also:
- Partial reprogramming
- Exosomes
- Albumin
- CDC42 inhibition
- An antibody against interleukin-11
- Deuterated fatty acids
- Oxytocin
The idea is to hit enough distinct forms of damage or dysfunction at once.
Dr. Nina Patrick: What would count as a home run?
Aubrey de Grey: Twelve months of lifespan extension in middle-aged mice would be enough. Even eight months might be sufficient to convince many of my colleagues that it is now respectable to discuss timeframes for LEV.
A lot of experts already understand that such studies matter, but they worry about career costs—such as grant reviewers judging them for sounding irresponsible.
Chapter 7: Why lifespan is the acid test, not healthspan claims
Phil Newman: Are these mainly approved therapeutics, or are they largely experimental?
Aubrey de Grey: Everything is motivated by what has been done in mice. If something is already in the clinic, that is a bonus, but it is not the main criterion.
We work in mice because they are short-lived. People can talk endlessly about healthspan, and healthspan does matter. I do not work on longevity for its own sake; I work on health. But critics will always say: “Did it live longer?” If the answer is no, they will accuse you of cherry-picking health measures.
So lifespan is the acid test.
Chapter 8: AI, AlphaFold, and in silico medicine accelerating biotech
Phil Newman: AI is everywhere in biomedical research right now. What kinds of data or experimental design are most urgently needed if AI is really going to accelerate rejuvenation science?
Aubrey de Grey: AI is helping in many different ways. Some of the most important advances in aging research have come from technologies that were not longevity-specific at all—things like induced pluripotent stem cells, CRISPR, and now AI tools such as AlphaFold.
That pattern will continue. AI is benefiting all of medicine, not just longevity.
There are also more targeted examples, such as Insilico Medicine, which has increasingly demonstrated an ability to accelerate drug development. That is important. But at the LEV Foundation we have limited resources, so we focus on the interventions with the strongest evidence for moving mouse lifespan.
Phil Newman: But is AI just creating a bigger downstream bottleneck—more candidate therapies than the current system can handle?
Aubrey de Grey: There are two ways to look at that. One is the world as it is today; the other is the world after society fully wakes up to aging.
If aging becomes a top-tier priority, then bottlenecks will be attacked as they were during Covid. Right now, though, public interest is still insufficient, so we need to streamline what we can within existing constraints.
That includes regulatory modernization, special zones for medical innovation, and experiments with more flexible jurisdictions. These are useful, but small relative to what could happen if the field gets its true breakthrough.
Phil Newman: What about ARPA-H and its recent longevity-related programs?
Aubrey de Grey: ARPA-H is making an enormous contribution, but it cannot do everything. It is funding ambitious work more aggressively than NIH usually does, and it is fortunate that it has program managers interested in this space. That is excellent.
But ARPA-H, like DARPA, still wants translational results on a relatively short timescale. So some things I think are important may still fall outside its remit.
Chapter 9: Aging vs disease, intrinsic capacity, and resilience metrics
Phil Newman: What are your thoughts on intrinsic capacity as a measure of functional aging? Could concepts like that help aging finally be treated as a disease?
Aubrey de Grey: There has already been progress in how aging is treated in disease classification systems, but yes, more would be good.
The first step is to abandon the idea that aging is not a disease. I often say that calling Alzheimer’s a disease is misleading—it is part of aging. The same is true for many other age-related conditions. There is no clean separation between “aging itself” and these named diseases.
Historically, people have measured function in terms of activities of daily living, and those are important predictors of both lifespan and quality of life. But they typically do not decline enough to be easily measurable until rather late.
That is where intrinsic capacity helps: instead of asking what people usually do, you ask what they are maximally capable of doing. That can reveal decline earlier.
And beyond that, there is resilience: you challenge the organism and see how well it responds. That may provide an even earlier and more sensitive readout.
Chapter 10: GLP-1 drugs and the barrier to preventive medicine
Phil Newman: Last year there was discussion about Novo Nordisk and Eli Lilly framing their GLP-1 drugs as longevity therapeutics. Will we look back and regard semaglutide-like drugs as early longevity medicines?
Aubrey de Grey: It would have been astonishing if drugs that help people lose substantial weight did not affect aging, because serious obesity is obviously harmful.
The more interesting point is that GLP-1 drugs have partly overcome a major barrier: society’s resistance to preventive medicine. People dislike the idea of taking medicine before they are sick, because they worry that it might itself cause harm.
GLP-1 drugs succeeded partly because they treat something people dislike having—obesity—even if obesity is not always thought of as a disease in the same way. So they sidestepped the usual resistance.
That is similar to what happened with statins, which gradually shifted from treatment to prevention over time. But it is frustrating that progress depends so much on luck. Medicine should be preventive by default.
Chapter 11: Longevity clinics, off-label use, and “nibbling around the edges”
Phil Newman: While all this research continues, what does the transition pathway look like? Longevity clinics? Prevention trials? Off-label use?
Aubrey de Grey: I do not think we can completely break the current cycle yet, but we can weaken it.
When I started, I was more or less alone in publicly making these arguments. Over time, more voices emerged, and different people reached different audiences. That matters.
I think the same is true for longevity clinics, trials, and off-label experimentation. They are nibbling around the edges, but the nibbling adds up. They make people more comfortable with the idea that aging may become medically controllable. So when a real laboratory breakthrough comes, the world will be less resistant.
Phil Newman: What about equity? How do we avoid a world in which only the ultra-wealthy benefit?
Aubrey de Grey: Again, look at Covid. Vaccines were not only for the wealthy.
Even after aging becomes a top social priority, it will still take perhaps ten years to develop workable treatments. That gives society time to prepare.
There is a humanitarian imperative for broad access, and in democracies perhaps also an electoral one. But the most important imperative is economic. Governments spend huge amounts keeping chronically ill people alive. If they can prevent people from becoming sick in the first place, the economic gains are enormous.
So it will be economically irrational for countries not to invest in making these therapies broadly available.
Chapter 12: The economic imperative and why every country must invest
Aubrey de Grey: This logic applies in poorer countries too. Average lifespan is now above 50 in every country, which means aging has become the dominant medical problem essentially everywhere. Even in countries with lower incomes, failure to invest in anti-aging medicine would ultimately be economically self-defeating.
Chapter 13: Overpopulation, pollution, and why the concern is overstated
Dr. Nina Patrick: Another common concern is overpopulation. Do you think that becomes the main ethical issue, or does access come first?
Aubrey de Grey: Those are two sides of the same coin—you cannot really have both at once in the way people often imply.
Overpopulation is greatly overstated. People would only get older at one year per year, so even under pessimistic assumptions population growth would unfold slowly.
If people say we already have too many humans, that is not really a space problem. It is more an environmental footprint problem—carbon emissions, plastics, pollution. But those are technological problems we are already trying to solve.
And in terms of literal space, the planet is not remotely full. It is a bad idea to decide what to do today based on speculative assumptions about a distant future centuries from now.
Chapter 14: How Aubrey’s predictions shifted over 20 years
Phil Newman: Looking back across your career, from SENS to the LEV Foundation, what has changed most in your thinking?
Aubrey de Grey: Surprisingly little. The biggest change was in my timelines. Around 2004 I said there was a 50% chance of reaching LEV by about 2030. By 2014 I had pushed that back into the late 2030s because progress during the preceding decade had been slow.
The good news is that since then, the slippage has stopped. I am still saying the late 2030s, because the pace of progress has improved so much.
Also, my classification of aging damage has remained fairly stable over time, which I see as evidence that we may already understand the major categories of age-related damage well enough that no huge new category is likely to appear unexpectedly.
Phil Newman: Quickfire round: what is the most common misconception about longevity science?
Aubrey de Grey: The idea that there is tension between healthspan and lifespan. I do not work on longevity for its own sake; I work on health. Longevity is a side effect of health.
Phil Newman: What aging mechanism deserves more attention?
Aubrey de Grey: The extracellular matrix. It is poorly turned over during normal life, and it matters a great deal for tissue biophysics, yet it gets too little attention.
Phil Newman: What intervention is currently overhyped?
Aubrey de Grey: Probably calorie-restriction mimetics, including NAD precursors and related ideas. They are not useless, but they are often oversold.
Phil Newman: If funding for aging research doubled or tripled tomorrow, where would you put it?
Aubrey de Grey: The issue is not simply total funding. It is how funding is distributed. Right now there is strong short-term bias both in academia and the private sector, so important long-term work often does not get done.
Chapter 15: What aging medicine might look like by 2040 and close
Phil Newman: If the repair-based approach succeeds, what might aging research and healthcare look like by 2040?
Aubrey de Grey: By 2040 we should at least know the answer, even if version 1.0 is only just emerging. But many details remain unknowable now: how personalized treatments will be, how many interventions people will need at once, how much surgery may be involved initially, and so forth.
Phil Newman: Aubrey, thank you very much for joining us.
Aubrey de Grey: Likewise. Thanks for having me.
Dr. Nina Patrick: If listeners want to find out more about the LEV Foundation, where should they go?
Aubrey de Grey: The website is levf.org. There is information there about previous and planned studies, and of course ways to support the work.
Phil Newman: Thanks for listening to Longevity Technology Unlocked. Stay curious, stay intentional, and keep investing in your future health.
Summary
This interview is a clear expression of Aubrey de Grey’s long-standing repair-based theory of rejuvenation and his idea of longevity escape velocity (LEV). His central claim is that it will likely be easier to repair accumulated age-related damage than to substantially slow the rate at which damage forms. If medicine can periodically restore people to a younger biological state, then each rejuvenation cycle could buy enough time for improved therapies to arrive before the next cycle is needed.
His practical benchmark is not human data yet, but a dramatic result in middle-aged mice. He argues that extending late-life mouse lifespan by roughly 8–12 months, rather than the current rough ceiling of about 4 months, would persuade scientists, public intellectuals, and eventually governments that aging is truly malleable. In his view, that would trigger a broader mobilization similar to the response seen during Covid.
He describes the LEV Foundation mouse program as a combinatorial intervention platform. The first study combined rapamycin, telomerase gene therapy, heterochronic bone marrow transplant, and a senolytic. The newer portfolio includes a wider mixture of interventions such as partial reprogramming, exosomes, albumin, cytokine targeting, CDC42 inhibition, deuterated fatty acids, oxytocin, and improved senolytics. His aim is not mainly to prove that these exact interventions will translate directly to humans, but to demonstrate that robust rejuvenation in a mammal is possible.
He also stresses several broader themes: AI is helpful but not sufficient on its own; lifespan remains the decisive endpoint because healthspan claims are easy to dispute; preventive medicine faces cultural resistance; GLP-1 drugs are important mostly because they softened that resistance; and future access to anti-aging therapies will be driven less by altruism than by the overwhelming economic logic of preventing chronic disease.
What is novel or interesting here
This is not novel in the sense of new science, but it is a useful and unusually concentrated statement of de Grey’s current position.
The most interesting points are these:
1. A very explicit “mouse first, society second” strategy
He is unusually candid that the mouse program is partly a social proof project. He is not primarily presenting it as a straightforward translational pipeline to humans. He wants a mouse result powerful enough to change the cultural and funding environment.
2. LEV framed as iterative re-rejuvenation rather than one-off cure
He gives a clean explanation of LEV as a sequence: restore a person enough to buy time, then use later improved medicine to restore them again. That iterative framing is clearer here than in many casual summaries of LEV.
3. Strong emphasis on combination therapy
He treats aging as a multi-damage engineering problem and argues that success will almost certainly require many simultaneous interventions, not one master drug.
4. Lifespan as the “acid test”
He explicitly pushes back against the field’s increasing comfort with softer endpoints. This is useful because much of current longevity discourse leans heavily on biomarkers, functional endpoints, or pathway modulation.
5. Extracellular matrix as underappreciated
His quickfire answer that the extracellular matrix deserves much more attention is notable. That is a less fashionable emphasis than senescence, reprogramming, or inflammation.
Critique
Overall assessment
This is a strong advocacy interview and a good strategic manifesto, but it is not a balanced scientific review. It mixes plausible high-level reasoning with speculative timelines, rhetorical shortcuts, and selective treatment of opposing evidence.
Strengths
Clear conceptual framework
De Grey is very good at making the repair paradigm intelligible. The “maintenance” analogy works well, and the iterative logic of LEV is easy to follow.
Correct emphasis that aging is multifactorial
He is right that meaningful rejuvenation will probably not come from a single intervention. The field increasingly supports multi-mechanism models involving senescence, stem-cell dysfunction, immune dysregulation, mitochondrial damage, extracellular changes, epigenetic drift, and other processes.
Realistic about risk in partial reprogramming
One of the strongest parts of the interview is that he does not portray partial reprogramming as solved. He openly says current approaches may elevate cancer risk and that this must be taken seriously.
Useful distinction between scientific truth and social adoption
He recognizes that even if science advances, regulation, public opinion, funding incentives, and clinical norms can still delay translation. That is an important and often ignored point.
Weaknesses
1. The mouse argument is rhetorically strong but scientifically slippery
He repeatedly implies that a sufficiently strong mouse lifespan extension result would transform the field. That may be true socially, but scientifically it is less decisive than he suggests.
A dramatic mouse result would indeed be important, but it would not resolve:
- species translation problems,
- long-term safety,
- human dosing complexity,
- interaction effects in older humans with co-morbidity,
- manufacturing and delivery issues,
- or the problem that mouse aging is not human aging in miniature.
So his benchmark is powerful as a field-shaping signal, but weaker as evidence for near-term human LEV.
2. Timelines remain highly speculative
The “50% chance in 12–15 years” claim is presented as probabilistic, but it still rests heavily on judgment rather than a transparent model. There is no clear quantitative framework linking current progress in mice, likely translational lag, clinical trial constraints, and real-world deployment. It is therefore better understood as an expert intuition than as a forecast.
3. He understates uncertainty around combinatorial interventions
He acknowledges possible surprises, but the actual problem is larger than that wording suggests. Combining multiple therapies aimed at different damage classes creates a major systems-level challenge:
- non-linear interactions,
- immune complications,
- cancer promotion,
- tissue-specific trade-offs,
- timing dependence,
- and patient heterogeneity.
The interview does not really grapple with how difficult clinical validation of such combinations would be.
4. “Aging is a disease” is rhetorically effective but conceptually messy
His insistence that Alzheimer’s is “part of aging” rather than truly a disease is provocative, but it risks oversimplifying disease classification. There is truth in the argument that many age-related diseases are manifestations of shared underlying aging processes. But collapsing disease and aging too fully can blur important distinctions in mechanism, diagnosis, and intervention.
5. He dismisses some counterarguments too quickly
The interview includes a few places where skepticism is brushed aside rather than engaged seriously:
- overpopulation concerns are treated as largely overblown,
- access inequality is framed as mostly solvable by economic incentives,
- and the Covid analogy is used very aggressively.
These arguments are not baseless, but they are more contestable than he allows.
For example, the Covid analogy is imperfect because:
- infectious disease creates immediate collective urgency,
- vaccine development had unusually clear endpoints,
- and emergency authorizations happened under very specific political conditions.
Aging lacks those exact features.
6. Sponsor segment sits awkwardly beside scientific seriousness
The Fatty15 advert sits in stark contrast to the interview’s scientific tone. That is more a production criticism than a criticism of de Grey himself, but it highlights a recurring problem in longevity media: serious scientific discussion is often mixed with supplement marketing, which can blur epistemic standards.
Bottom line
This is a good, coherent advocacy interview and one of the clearer summaries of Aubrey de Grey’s current worldview.
Its core message is:
- aging should be treated as an engineering-style repair problem,
- combination rejuvenation in mice is the near-term proof point,
- a large enough mouse result could flip the social and scientific narrative,
- and once that happens, medical, regulatory, and financial systems could shift much faster than most people expect.
The strongest parts are the clarity of the repair framework, the emphasis on combination therapy, and the realism about some safety risks such as reprogramming and cancer.
The weakest parts are the speculative timelines, the heavy reliance on mice as a social turning point, and the tendency to compress complex objections into brisk rhetorical dismissals.
My overall judgment: strategically interesting, scientifically provocative, but not evidentially strong enough to justify confidence in the stated timelines.
If you want, I can also turn this into a claim-by-claim table with columns for claim, evidence cited in the interview, likely strength, and critique.